Clinical trials in gynecologic oncology: Past, present, and future
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynaecology,Oncology
Reference70 articles.
1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N. Engl. J. Med.,1996
2. Improved survival with bevacizumab in advanced cervical cancer;Tewari;N. Engl. J. Med.,2014
3. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicenter, open-label, randomized, phase 3 trial;Coleman;Lancet Oncol.,2017
4. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852);Thaker;Ann. Oncol.,2017
5. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer;Chan;N. Engl. J. Med.,2016
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists;Gynecologic Oncology;2024-05
2. Intelligent Puncture Equipment in Sampling of Gynecological Tumors;Cyber Security Intelligence and Analytics;2022
3. The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation;Gynecologic Oncology;2021-07
4. Effect of enhanced recovery after surgery management combined with nano-antibacterial dressing during perioperative nursing practice on rehabilitation of patients with gynecological tumor;Materials Express;2021-07-01
5. Future perspectives and new directions in chemosensitizing activities to reverse drug resistance in gynecologic cancers: Emphasis on challenges and opportunities;Overcoming Drug Resistance in Gynecologic Cancers;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3